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A B S T R A C T
The aging process is a normal stage in development characterized by the gradual deterioration of all life functions. As
far as reproduction is concerned, aging is characterized by a significant limitation of fertility in both sexes. This process
is, at least partially, attributed to the action (or loss of action) of sex steroids, coinciding with low activity of the pitu-
itary-gonad axis. From an anthropological point of view, the study of reproductive aging is a unique opportunity to in-
vestigate various environmental and endogenous factors influencing sexual behavior and, thus, playing a significant
role in human biology. Various techniques are now widely available to allow the detailed examination of reproductive
hazards using only minor samples of genetic material. These methods are highly sensitive and specific and allow the
characterization of distortions at subcellular and even molecular level. This short review briefly summarizes the current
understanding of reproductive aging, as well as its potential clinical and anthropological impact.
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Introduction
In older men, as opposed to aged women in which
menopause marks the end of their reproductive period,
maintenance of spermatogenesis and continuation of an-
drogen production, although in diminished quantities,
sustain sexuality and fertility1. This situation may per-
sist until an advanced age unless pathological conditions,
particularly those implicating an increase of reactive ox-
ygen species (ROS), impair semen quality. In the absence
of pathology, spermatogenesis continues until a very old
age (95 years), although a gradual decline of endocrine
function in conjunction with deterioration in some of the
sperm parameters is normally observed, reflecting the
age-related structural changes that occur in the testis2.
Within the aging male population the gradual decrease in
androgen plasma levels has been considered the prelude
of entering the third age (andropause). Within the spec-
trum of changes observed in aged men, several symptoms
can be distinguished, namely decreased libido, psycholog-
ical and emotional disturbances, erectile dysfunction, de-
crease in muscle strength and bone density, all contribut-
ing greatly in the distinct social and biological role of the
elderly in any society. Concerning general semen param-
eters, a reduction of approximately 25% is observed in all
major qualities and this implies an analogous reduction
in the fertilizing ability of older in comparison with
younger men.
Gonadal Status of the Old Man
Within the testis of old men, a smaller number of
Leydig cells can be detected in the interstitial tissue and
those that remain accumulate the »ageing« pigment lipo-
fuscin, crystalline inclusions, and residual bodies3. A
mechanism involving an age-related increase in cyclooxy-
genase-2 activity and its tonic inhibition of steroido-
genesis in rat Leydig cells has been suggested4. Smaller
numbers of germinal and Sertoli cells are also counted.
The ultrastructure of this progressive testicular involu-
tion reveals multinucleated and degenerating germ cells
that are phagocytosed by Sertoli cells which appear va-
cuolated with lipid droplets accumulated in their cyto-
plasm5. Concomitant increase in the thickness of the
tunica propria outlining the seminiferous tubules, as
well as the tunica albuginea, is also observed. Age-related
alterations of spermatogenesis are described by Holstein,
who noticed reduction in dark type and intratubular
clustering of pale type spermatogonia in the spermatic
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epithelium of aged men6. Additionally, he reported the
presence of spermatocytes (type I) with large nuclei and
an arrest of spermatogenesis at this stage concomitant
with numerous malformations of spermatids. Neverthe-
less, this histological pattern is usually found in small ar-
eas of the aging testis with a varying frequency among
individuals. Inversely, seminiferous tubules with com-
plete spermatogenesis could be found in the testis until
advanced age (95 years), according to the data reported
from a study of 36 men, 61–102 years of age, among
which 17 were found having an efficient spermatogenesis
(the oldest was 95 years old). The others presented
spermatogenesis arrest and in 15 of them this situation
was observed in a precocious stage1. These histological
alterations at the testicular level are related with the re-
duction in blood testosterone concentration and this phe-
nomenon influences many physiological functions, such
as bone mineral density (BMD), muscle strength and
libido8.
Decline in Testosterone Production
with Age
The age-associated decline in physical and reproduc-
tive competence following the decline in testicular func-
tion, Leydig cell numbers and androgens, is observed in
the elderly and is commonly described as andropause or
late onset hypogonadism (LOH)8,9. This is a clinical and
biochemical entity which combines diminution of testos-
terone levels below the young adult healthy male refer-
ence range with low libido and sexual activity, erectile
dysfunction, decreased muscle mass and strength, osteo-
porosis accompanied by increased risk of fractures, obe-
sity and increase in visceral fat, weakness, diminution of
body hair, depression or irritability and sleep distur-
bances9,10. The anabolic effects of androgens are neces-
sary for the maintenance of bone density and the slow
decline observed with age is linearly associated with low
bone mass11. In addition to bone loss, a number of other
extra-osseous factors make a greater contribution to
male osteoporosis: thus, 50–70% of cases are related to
hypercorticism, alcohol abuse, smoking, liver or gastro-
intestinal disorders.
These symptoms are analogous to those observed in
young males suffering from hypogonadism, which can be
easily evaluated using ADAM (Androgen Deficiency in
Aging Males) questionnaire or AMSS (Ageing Male
Symptom Score)9. Nevertheless, these are not considered
specific to the low levels of testosterone but rather indic-
ative of androgen insufficiency10,12-13.
Consequent to the gradual decrease of testicular an-
drogen production after 40 years of age, the function of
multiple organs is affected leading to the progressive de-
velopment of various symptoms having a detrimental im-
pact on life quality. After the age of 50 years, the decline
in serum and free testosterone levels is between 0.4 and
1.2% per year, respectively14. At the age of 75 years, mean
plasma testosterone levels are only 65% of those found in
young adults but there are inter-individual variations
and, importantly, a quarter of men aged over 75, have
testosterone levels comparable to those of young men15.
Multiple causes are hiding under the etiology of these
symptoms. For example, a correlation between decreased
libido and low plasma testosterone levels might exist, but
other causes such as depression, illness or the death of a
spouse, should also be considered. This situation can be
improved following testosterone therapy in 70–80% of af-
fected persons1. Defective erections are also associated
with low testosterone levels. This implies decrease in ni-
tric oxide synthase (NOS) enzyme, an endothelium-de-
rived relaxation factor (former ERDF) implicated in pe-
nile erection along with other neurotransmitters. In this
case testosterone treatment improves the quality of erec-
tions produced by phosphodiesterase-5-inhibitors16.
Relatively recently, the association of hypogonadism-
-related symptoms and signs to age has been evaluated in
a series of 1647 (mean age 52.4±13.1 years) male pa-
tients with sexual dysfunction. From the hormonal and
biochemical data and psychological parameters it was
shown that low testosterone (T) was associated with
higher waist circumference and triglyceride levels and
promptitude to develop metabolic syndrome. In the old-
est age group, subjects with higher T levels showed
better lipid profile and penile flow. Thus, older men pres-
ent with increasing frequency an association of low T
with sexual and metabolic dysfunction17.
Laboratory assessment of hypogonadism is necessary
in all these cases and implies measurements of total se-
rum testosterone levels (ÔÔ <200 ng/dL). Borderline re-
sults (ÔÔ >200 ng/dL to ÔÔ <350 ng/dL), impose re-
peated assay with determination of bioavailable serum
testosterone (bT) and free T (FÔ), but threshold values
for bioavailable testosterone are not generally offered. It
is well known that after the age of 55 years the gradual
reduction of androgens affects both TT and FT. TT re-
duction is 0.8% per year and this results in a mean value
of 60% in men 75 years old compared to that obtained in
young men (30 years). More important is the reduction of
FT, given that it starts earlier and it is calculated at
about 1.4% per year so that at 75 years of age its mean
value corresponds to the 40% of the value seen in young
men. Furthermore, with advanced age a gradual increase
of SHBG occurs, while the circadian rhythm of T secre-
tion is lost. It should also be noted that estrogens present
a gradual decrease in aging men as well, although less
evident compared to that of androgens18,19. This can al-
ternatively be interpreted as a relative increase of the es-
trogen/androgen ratio due to increased peripheral aro-
matization, with further implications for their respective
effects. In any case, for the establishment of a diagnosis
of hypogonadism it is important to gather total testoster-
one measurements rather than free testosterone values
only10. Harmonization of immunological assays can dis-
tinguish normal to low testosterone men but perfor-
mance of mass spectrometry offers an accurate and reli-
able method for evaluating plasma testosterone levels.
Other causes affecting androgen levels in the aging
man include critical illness which is characterized by










hypogonadotropic hypogonadism due to impairment of
the hypothalamo-pituitary-testicular axis. Also, chronic
diseases such as diabetes mellitus, metabolic syndrome,
chronic renal disease, chronic respiratory disease, chro-
nic infections and acute infectious diseases. The situa-
tion is aggravated by smoking, consumption of alcohol or
drugs, such as anabolic steroids and glucocorticoids, obe-
sity and secondary hypogonadism. The laboratory confir-
mation of hypogonadism is given from the reduced levels
of Testosterone (Total serum Testosterone <200 ng/dL).
It should be noted that the normal range of serum testos-
terone is very wide and fluctuates between 300 and 1100
ng/dl. Diurnal variations are observed with the higher
rate (peak) being at 08.00 in the morning and the lower
(nadir) at 22.00 in the night. This circadian rhythm of
testosterone secretion follows the pulsatile secretion of
the LH.
Hypogonadism is the main indication for testosterone
substitution in ageing males20. Therapy aims to prevent
or reverse hypotestosteronemia, increased negative feed-
back of testosterone in the pituitary gland, irregular pro-
duction of GNRH from the hypothalamus and loss of cir-
cadian rhythm in testosterone secretion. It should be
noted, however, that not only the reduced level of go-
nadal steroids, but also the secretion of other endocrine
glands shows alterations in the elderly. Detailed descrip-
tion of these adaptive changes is still missing, and there
is no concomitant estimation of other hormones e.g.
growth hormone, insulin-like growth factor-1, oestradiol,
thyroid hormones, cortisol, ACTH, dehydroepiandroste-
rone sulfate and melatonin quantifications are not per-
formed unless there is suspicion of pertinent disor-
ders10,21,22. Small-scale clinical studies have shown that it
is beneficial to boost growth hormone and IGF-1 levels
for periods of up to 12 months, and testosterone for up to
36 months, to reverse at least some age-related changes
in body composition23.
Old men receiving testosterone claimed satisfactory
results on reproductive competence and well-being. Until
recently, it was advisable to avoid side effects by keeping
plasma testosterone levels within the physiological range
for the entire period between two consecutive doses. But
this is no longer acceptable because a large variation of
the so called physiological thresholds is observed among
individuals and the amount of androgen required for ev-
ery biological function is different24. Hence, the results of
larger, long term, well-controlled studies are needed to
establish a stronger recommendation regarding routine
testosterone substitution in elderly men. For the time be-
ing, the therapeutic goal targets to mid – lower young
adult levels of serum testosterone25. In men suffering
from osteoporosis and hypogonadism testosterone ad-
ministration proved beneficial and their BMD was re-
stored to the level of aged-matched men who had no
shortage of testosterone, provided that treatment was
given over a period of 3 years26.
Concerning the choice of testosterone preparations, it
seems that transdermal gels and intramuscular testos-
terone undecanoate administration are the best suited
when taking into account the above mentioned criteria.
In any case testosterone therapy in the ageing male has
to be monitored closely, especially regarding erythro-
poiesis and prostate epithelial proliferation. Concerning
the latter, an absolute contra-indication for testosterone
supplementation is clinical prostatic carcinoma. Men
treated with androgen depletion therapy for prostate
cancer develop severe osteoporosis and are in strong risk
of bone fracture27.
Sex Steroids and their Effect on the
Metabolic Syndrome
In the aging male population, low SHBG and free tes-
tosterone coincides with an increased prevalence of the
MS components, i.e. obesity, dyslipidemia, hypertension
and insulin resistance/diabetes mellitus. In certain com-
parative studies, it has been demonstrated that sex hor-
mone-binding globulin (SHBG) and testosterone levels
are in fact a significant determinant of fat accumulation,
both subcutaneously and in the abdomen, bearing a
clearly protective role. However, this benefit has not ex-
tended to other major parameters of the MS, such as in-
sulin resistance itself, implying a more complex mecha-
nism for their sustained presence in the aging male
population28–30.
Findings such as those described above have led to a
series of studies on the necessity of hormonal interven-
tion and androgen substitution in the elderly (late-onset
hypogonadism model). In particular, testosterone decrea-
se has been found to be proportional to the metabolic and
functional features of male aging, such as impaired adi-
pose tissue-lean body mass ratio, muscle weakness, in-
creased bone decomposition and proneness to develop
the MS and its various life-threatening complications.
However, tissue sensitivity to androgens varies consider-
ably and, thus, the limit from desired function to adverse
effects is not easily determined. Indeed, results indicate
some beneficial role of androgen substitution (e.g. lower
total cholesterol) but simultaneously unwanted phenom-
ena (e.g. lower HDL-cholesterol). The fact that other
studies have failed to verify this finding or even propose
an opposite effect (improved HDL-cholesterol) only shows
that several unidentified confounders may still be pres-
ent and no generalized recommendation for androgen
substitution can be reasonably adopted at this point31–33.
Aging and the Quality of the Ejaculate
(Sperm Parameters)
From earlier studies it has been reported that age has
only minimal effects on the quality of the ejaculate34.
However, recent data comparing semen parameters from
young and old men groups state that in older men semen
volume production is reduced almost by 50% and further
associated with low sperm count35,36. Others claimed that
age seems to affect some semen parameters, such as mo-
tility and morphology of spermatozoa, while there is no
significant difference on sperm concentration between










the two groups35,37. In fact, a higher percentage of sper-
matozoa with abnormal morphology, abnormal tail, pres-
ence of cytoplasmic droplet, reduced vitality and increa-
sed index of teratozoospermy (TZI) has been observed.
Nevertheless, the rate of head and neck abnormalities
has been reported not to differ importantly between
groups of young and old men37.
In another study among infertile patients and normal
men, sperm motility was also reduced and this was the
only parameter affected in the older age group38. An as-
sociation of reduced motility with significant increase of
spermatozoa DNA fragmentation has been observed in
the same study. Several other studies demonstrated that
older men seem to produce more spermatozoa with dou-
ble strand DNA breaks and showed a strong association
of DNA Fragmentation Index (DFI) with age38–44. One
possible way to interpret this could lead back to the ef-
fects of oxidative stress, implying that the increase in
DNA fragmentation in older men may result from a
higher exposure to oxidative stress in their reproductive
tracts45,46. Another may implicate the increased produc-
tion of spermatozoa with fragmented DNA due to a re-
duced effectiveness of Fas-mediated apoptosis and defi-
ciencies in the ligation of DNA strand breaks during
chromatin packaging47,48. In any case, recent data con-
firm the effect of age on sperm DNA damage in infertile
male population using the TUNEL technique for the
evaluation of sperm DNA fragmentation and found a sig-
nificant increase in sperm DFI with age49. This was in
contrast with an earlier study showing no association be-
tween DNA damage and age in spermatozoa collected af-
ter swim-up wash, which can possibly be considered the
culprit by eliminating the fraction of spermatozoa bear-
ing fragmented DNA50.
Molecular Cytogenetics
Advancing paternal age has been implicated in failure
of fertilization, spontaneous abortions and unsuccessful
pregnancies. The use of spermatozoa with DNA damage,
whose rate is directly correlated with age, has been asso-
ciated with an accompanying increased risk for transmis-
sion of genomic errors to the offspring51, 52. Furthermore,
histomorphometric studies of testes in old men showed
an increased aneuploidy rate in postmeiotic cells in the
seminiferous epithelium2. Age induces relatively minor
changes in sperm chromosomes, but when the male part-
ner is more than 50 years old, fertilizing ability seems to
decrease. Assays in clinical use include: 1) Karyotype and
Fluorescent in situ hybridization-FISH53, 2) PCR detec-
tion of microdeletions of the Yq54 and 3) TUNEL and
Chromomycin A3 for the detection of DNA damage and
chromatin packaging abnormalities55–57.
Finally, in semen from aged men chromosome abnor-
malities, namely linear increase of diploidy and disomy of
chromosome 9, have been observed37. Increased sperm
DNA damage has been associated with chromosomal ab-
normalities, developmental loss and birth defects in
mouse model systems58 as well as an increase in the per-
centage of human embryos that failed to develop after
ICSI59. The evaluation of the spermatozoon nucleus as a
novel target in previously unexplained male infertility is
an important breakthrough in reproductive biology and
remains a challenge for large-scale epidemiological re-
search within the context of trans-regional population
anthropology. The application of the relevant molecular
diagnostic techniques requires the development of ac-
credited biomedical laboratories supervised by adequate,
specialized academic and technical staff60,61.
Conclusions
The increase in the number of researchers and units
involved with fertility studies in males will enable the ex-
ploration of various classic anthropological questions.
These include, for instance, evolutionary dynamics among
various human populations (using the male to male
transfer of the Y chromosome as a heredity index), demo-
graphic trends and inequalities (using the male fertility
potential to predict future birth rates), inter-species
comparative genetics studies (estimating the common
characteristics of reproductive biology and the aging pro-
cess in mammals, with particular reference to primates)
and paternity identification, in cases of forensic and/or
archeological-historical interest. Therefore, the potential
gain from such scientific applications justifies the in-
creased academic interest in male reproductive biology in
recent years and calls for interdisciplinary cooperation in
the field.
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PLODNOST U STARIJIH MU[KARACA: MOLEKULARNI PUTEVI U ANTROPOLOGIJI STARENJA
S A @ E T A K
Starenje je normalna postaja u procesu karakteriziranom kao postupna propadanje svih `ivotnih funkcija. [to se
reprodukcije ti~e, starenje je karakterizirano zna~ajnim ograni~enjem plodnosti obaju spolova. Ovaj process mo`e se
barem djelomi~no pripisati djelovanju (odnosno smanjenom djelovanju) spolnih steroida. Iz antropolo{ke perspective,
istra`ivanje reproduktivnog starenja je jedinstvena prilika za istra`iti razli~ite okoli{ne i endogene ~imbenike koje utje-
~u na seksualno pona{anje i tako igraju zna~ajnu ulogu u biologiji ~ovjeka. Danas su {iroko dostupne razne tehnike za
detaljnu analizu uz minorne koli~ine geneti~kog materijala. Ove metode su izrazito osjetljive i specifi~ne te omogu}uju
karakterizaciju distorzija na subcelularnom te ~ak i molekularnom nivou. Ovaj kratak pregled sa`ima sada{nja razumi-
jevanja reproduktivnog starenja kao i njihove potencijalne klini~ke i antropolo{ke u~inke.
R. Angelopoulou et al.: Fertility in the Aging Male, Coll. Antropol. 37 (2013) 2: 657–661
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